{
  "trial_id": "NCT00348595",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, Gender, Baseline PSA level, Prior local treatment (surgery or radiation), Time since last local treatment, Prior systemic chemotherapy, Prior hormonal therapy, Prior biologic or vaccine therapy, Serum testosterone level, Ability to take aspirin, History of thrombotic events, Presence of other malignancies, Serious medical conditions, Laboratory abnormalities, Psychiatric illness, Hypersensitivity to thalidomide, Known brain metastases, HIV status, Hepatitis status, Evidence of metastatic disease, PSA values during pre-study period, Number of prior biologic or vaccine therapies.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Gender"
        ],
        [
          "Local therapy",
          "Prior local treatment (surgery or radiation)"
        ],
        [
          "Serum testosterone",
          "Serum testosterone level"
        ],
        [
          "Prostate Specific Antigen (PSA)",
          "Baseline PSA level"
        ],
        [
          "PSA doubling time (PSADT)",
          "PSA values during pre-study period"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Race and Ethnicity Not Collected",
        "Region of Enrollment",
        "Gleason score",
        "Pre-treatment PSA slopes"
      ],
      "remaining_candidate_features": [
        "Time since last local treatment",
        "Prior systemic chemotherapy",
        "Prior hormonal therapy",
        "Prior biologic or vaccine therapy",
        "Ability to take aspirin",
        "History of thrombotic events",
        "Presence of other malignancies",
        "Serious medical conditions",
        "Laboratory abnormalities",
        "Psychiatric illness",
        "Hypersensitivity to thalidomide",
        "Known brain metastases",
        "HIV status",
        "Hepatitis status",
        "Evidence of metastatic disease",
        "Number of prior biologic or vaccine therapies."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, Baseline PSA, PSA Doubling Time (PSADT), Serum Testosterone, Prior Local Treatment (Surgery/Radiation), Prior Systemic Therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Serum testosterone",
          "Serum Testosterone"
        ],
        [
          "Prostate Specific Antigen (PSA)",
          "Baseline PSA"
        ],
        [
          "PSA doubling time (PSADT)",
          "PSA Doubling Time (PSADT)"
        ],
        [
          "Local therapy",
          "Prior Local Treatment (Surgery/Radiation)"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Race and Ethnicity Not Collected",
        "Gleason score",
        "Pre-treatment PSA slopes"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Prior Systemic Therapy"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, Prostate Cancer Diagnosis Duration, Baseline PSA, Gleason Score, Prior Local Treatment, Prior Systemic Therapy, Serum Testosterone Level, BMI, Systolic Blood Pressure, Diastolic Blood Pressure.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Gleason score",
          "Gleason Score"
        ],
        [
          "Local therapy",
          "Prior Local Treatment"
        ],
        [
          "Serum testosterone",
          "Serum Testosterone Level"
        ],
        [
          "Prostate Specific Antigen (PSA)",
          "Baseline PSA"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Race and Ethnicity Not Collected",
        "PSA doubling time (PSADT)",
        "Pre-treatment PSA slopes"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Prostate Cancer Diagnosis Duration",
        "Prior Systemic Therapy",
        "BMI",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, race, ethnicity, weight, height, body mass index (BMI), prostate cancer stage, Gleason score, PSA at diagnosis, time since diagnosis, time since local treatment, type of local treatment, prior systemic therapies, testosterone level, Eastern Cooperative Oncology Group (ECOG) performance status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Gleason score",
          "Gleason score"
        ],
        [
          "Local therapy",
          "type of local treatment"
        ],
        [
          "Serum testosterone",
          "testosterone level"
        ],
        [
          "Prostate Specific Antigen (PSA)",
          "PSA at diagnosis"
        ]
      ],
      "remaining_reference_features": [
        "Sex: Female",
        "Male",
        "Race and Ethnicity Not Collected",
        "Region of Enrollment",
        "PSA doubling time (PSADT)",
        "Pre-treatment PSA slopes"
      ],
      "remaining_candidate_features": [
        "race",
        "ethnicity",
        "weight",
        "height",
        "body mass index (BMI)",
        "prostate cancer stage",
        "time since diagnosis",
        "time since local treatment",
        "prior systemic therapies",
        "Eastern Cooperative Oncology Group (ECOG) performance status"
      ]
    }
  }
}